Form 10-Q · Quarterly report
Monster Beverage 10-Q, filed Aug 7, 2026
- Filed
- CIK
- 0000865752
- Accession no.
- 0001104659-26-092193
Summary
Monster Beverage reported second-quarter 2026 net sales of $2.54 billion, up 20.2% from $2.11 billion a year earlier, and net income of $584.5 million, or $0.59 per diluted share, up 19.6%. Sales outside the United States rose 34.6% to $1.16 billion, and Coca-Cola Europacific Partners accounted for about 16% of net sales.
Key points
- Net sales for the quarter ended June 30, 2026 were $2.54 billion, a 20.2% increase, with foreign currency changes adding a favorable $48.5 million; on a currency-adjusted basis sales rose 17.9%.
- The Monster Energy Drinks segment generated $2.36 billion of net sales, 92.8% of the total, while Strategic Brands contributed $143.7 million, Alcohol Brands $32.2 million and Other $5.4 million.
- Energy drink case sales rose 22.3% to 304.9 million 192-ounce case equivalents for the quarter and 25.3% for the six months.
- Gross profit was $1.42 billion, or 55.9% of net sales, and operating income was $740.4 million, or 29.2% of net sales.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION Overview We develop, market, sell and distribute energy drink beverages and concentrates for energy drink beverages, primarily under the following brand names: ● Monster Energy® ● Full Throttle® ● Monster Energy Ultra® ● Burn® ● Rehab Monster® ● Mother® ● Monster Energy® Nitro ● Nalu® ● Java Monster® ● Ultra Energy® ● Punch Monster® ● Play® and Power Play® (stylized) ● Juice Monster® ● Relentless® ● Reign Total Body Fuel® ● BPM® ● Reign Storm® ● BU® ● StormTM ● Samurai® ● Bang Energy® ● Live+® ● FLRTTM ● Predator® ● NOS® ● Fury® We also develop, market, sell and distribute craft beers, FMBs and hard seltzers under a number of brands, including Jai Alai®…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.